Table 3.
Neoantigens for adoptive T cell therapy in clinical trials.
| Neoantigen | Disease | Intervention | Patient number | Phase | Country | NCT number |
|---|---|---|---|---|---|---|
| EGFRvIII | Esophagus Cancer, Hepatoma Glioma, Gastric Cancer |
CAR-T/TCR-T cells immunotherapy | 50 | I/II | China | NCT03941626 |
| Glioblastoma | CAR-EGFRvIII T cells | 7 | I | US | NCT03726515 | |
| Recurrent Glioblastoma | EGFRvIII-CARs | 24 | I | US | NCT03283631 | |
| Glioblastoma Multiforme | Anti-EGFRvIII CAR T cells | 20 | I | China | NCT02844062 | |
| Residual or Recurrent EGFRvIII+ Glioma | CAR-EGFRvIII T cells | 11 | I | US | NCT02209376 | |
| KRAS mutant | Gastrointestinal Cancer Pancreatic Cancer Gastric Cancer |
Anti-KRASG12D mTCR PBL | 70 | I/II | US | NCT03745326 |
| Pancreatic Cancer Gastric Cancer Gastrointestinal Cancer Colon Cancer Rectal Cancer |
Anti-KRASG12V mTCR PBL | 110 | I/II | US | NCT03190941 | |
| Tn-MUC1 | Advanced Esophageal Cancer | Anti-Tn-MUC1 CAR-T cells PD-1 knockout Engineered T cells | 20 | I/II | China | NCT03706326 |
| Intrahepatic Cholangiocarcinoma | Tn-MUC-1 CAR-T cell immunotherapy | 9 | I/II | China | NCT03633773 | |
| Lung Neoplasm Malignant Non-small Cell Lung Cancer |
Anti-Tn-MUC1 CAR-T Cells and PD-1 Knockout Engineered T Cells | 60 | I/II | China | NCT03525782 | |
| Advanced Solid Tumor | Anti-CTLA-4/PD-1 expressing Tn-MUC1-CAR-T | 40 | I/II | China | NCT03179007 | |
| Pancreatic Neoplasms | Dendritic cells pulsed with Tn-MUC-1/WT-1 peptides | 30 | I/II | Belarus | NCT03114631 | |
| Hepatocellular Carcinoma Non-small Cell Lung Cancer Pancreatic Carcinoma |
Anti-Tn-MUC1 CAR-pNK cells | 10 | I/II | China | NCT02839954 | |
| IDH1 mutant | Glioma | Dendritic cells | 30 | NA | China | NCT02771301 |
EGFRvIII, epidermal growth factor receptor variant III; NA, not available; mTCR PBL, mutated TCR peripheral blood lymphocyte; Tn-MUC-1, Tn (GalNAcα1-O-Ser/Thr) glycoform of MUC1; WT, wild type; pNK cell, peripheral natural killer cell; IDH-1, Isocitrate dehydrogenase 1.